ADVANCE (atogepant)
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)
Atogepant, an oral CGRP receptor antagonist, reduces monthly migraine days in episodic migraine preventive therapy.
Source publication
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine (ADVANCE)
—
Sponsor
Allergan
Principal investigator
Joel Trugman, MD
Population
Episodic Migraine; n=910
Primary endpoint
Change From Baseline in Mean Monthly Migraine Days Across the 12-Week Treatment Period
Methodology notes
Full methodology is under curation. This project aggregates 3 seeded claims across three temporal layers. The replication spec, pre-registered analysis, and version history will appear here as the project matures.
Funding progress
$2.9M / $3.8M
78%
Funding displayed here is indicative of collaborator interest. Sciync does not broker money, grants, or securities.
Temporal layers
Published findings under validation
1
Active replication in progress
1
Forecast horizons pending resolution
1